

Andres Cervantes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9003256/publications.pdf>

Version: 2024-02-01

234
papers

25,150
citations

28242

55
h-index

7340

152
g-index

242
all docs

242
docs citations

242
times ranked

26223
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
2	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	13.9	1,843
3	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	0.6	1,233
4	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v38-v49.	0.6	1,212
5	Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2696-2704.	13.9	1,142
6	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv22-iv40.	0.6	1,126
7	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii1-iii9.	0.6	910
8	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4706-4713.	0.8	909
9	Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi64-vi72.	0.6	874
10	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi81-vi88.	0.6	833
11	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 29-42.	5.1	739
12	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
13	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 928-936.	5.1	661
14	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , 2017, 28, 1713-1729.	0.6	654
15	Integration of oncology and palliative care: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2018, 19, e588-e653.	5.1	452
16	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMOâ€‘ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018, 29, 44-70.	0.6	432
17	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. <i>Annals of Oncology</i> , 2010, 21, v93-v97.	0.6	384
18	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368

#	ARTICLE	IF	CITATIONS
19	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	1.3	349
20	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii10-iii20.	0.6	244
21	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1165-1176.	0.5	237
22	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 801-805.	0.6	235
23	European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. <i>Annals of Oncology</i> , 2018, 29, 36-43.	0.6	220
24	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020, 31, 1320-1335.	0.6	219
25	First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. <i>Oncologist</i> , 2012, 17, 15-25.	1.9	192
26	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	3.2	181
27	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014, 111, 330-339.	0.3	179
28	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	3.2	179
29	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021, 39, 708-724.e11.	7.7	175
30	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , 2019, 30, 1804-1812.	0.6	174
31	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. <i>Cancer Treatment Reviews</i> , 2020, 86, 102015.	3.4	173
32	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
33	Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014, 40, 584-591.	0.5	162
34	Unmet needs and challenges in gastric cancer: The way forward. <i>Cancer Treatment Reviews</i> , 2014, 40, 692-700.	3.4	156
35	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 60-67.	3.4	150
36	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020, 31, 334-351.	0.6	138

#	ARTICLE	IF	CITATIONS
37	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113.	7.7	136
38	Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1558-1571.	0.6	136
39	Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4764-4774.	3.2	132
40	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123
41	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
42	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2022, 28, 507-517.	3.2	104
43	Definition of the Rectum. <i>Annals of Surgery</i> , 2019, 270, 955-959.	2.1	96
44	JSCO, ESMO, ASCO, JSMO, TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. <i>Annals of Oncology</i> , 2020, 31, 861-872.	0.6	94
45	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , 2011, 117, 3118-3125.	2.0	93
46	Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. <i>Annals of Oncology</i> , 2021, 32, 590-599.	0.6	91
47	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4006-4006.	0.8	84
48	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
49	Context matters: consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019, 30, 520-527.	0.6	80
50	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , 2008, 19, v103-v107.	0.6	77
51	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , 2010, 21, 1537-1545.	0.6	77
52	Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	68
53	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1557-1565.	0.6	64
54	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 877-885.	3.2	59

#	ARTICLE	IF	CITATIONS
55	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	2.9	57
56	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	1.2	55
57	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3568.	0.8	53
58	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387.	3.2	49
59	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
60	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1639-1649.	3.2	47
61	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
62	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019, 123, 146-154.	1.3	46
63	Molecular biology of gastric cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 208-215.	1.2	44
64	Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. <i>Annals of Oncology</i> , 2014, 25, 1485-1492.	0.6	43
65	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , 2021, 32, 1496-1510.	0.6	42
66	Oncological emergencies. <i>Annals of Oncology</i> , 2004, 15, iv299-iv306.	0.6	41
67	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	0.6	40
68	Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. <i>PLoS ONE</i> , 2017, 12, e0177331.	1.1	40
69	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. <i>ESMO Open</i> , 2018, 3, e000425.	2.0	39
70	Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019, 5, 1-22.	0.5	39
71	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019, 9, 7665.	1.6	36
72	Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015, 6, 26935-26945.	0.8	35

#	ARTICLE	IF	CITATIONS
73	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019, 4, e000470.	2.0	35
74	Oncology for medical students:. <i>Cancer Treatment Reviews</i> , 2007, 33, 419-426.	3.4	34
75	Undergraduate training in oncology: An ESO continuing challenge for medical students. <i>Surgical Oncology</i> , 2012, 21, 15-21.	0.8	34
76	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , 2018, 63, 156-171.	3.4	34
77	Preclinical models for precision oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 239-246.	3.3	34
78	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , 2009, 11, 787-798.	1.2	33
79	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. <i>Modern Pathology</i> , 2019, 32, 306-313.	2.9	31
80	The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020, 25, e451-e459.	1.9	30
81	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3611.	1.7	30
82	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	3.2	29
83	The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. <i>Annals of Oncology</i> , 2018, 29, 1099-1107.	0.6	29
84	Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 684-693.	0.7	29
85	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 994.	1.7	29
86	Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102263.	3.4	29
87	Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. <i>Annals of Oncology</i> , 2018, 29, 2033-2036.	0.6	28
88	Gastric cancer: ESMO's "ESSO" ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014, 110, 189-194.	0.3	27
89	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 124-135.	3.4	27
90	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	3.2	27

#	ARTICLE	IF	CITATIONS
91	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 496-505.	1.3	26
92	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 1874-1881.	2.9	26
93	An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. <i>Journal of Clinical Oncology</i> , 2004, 22, 3512-3512.	0.8	25
94	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. <i>Cancer</i> , 1995, 76, 559-563.	2.0	24
95	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015, 26, 1936-1941.	0.6	24
96	The multidisciplinary management of gastro-oesophageal junction tumours. <i>Digestive and Liver Disease</i> , 2016, 48, 1283-1289.	0.4	24
97	Adjuvant chemotherapy and relative survival of patients with stage II colon cancer – A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. <i>European Journal of Cancer</i> , 2016, 63, 110-117.	1.3	24
98	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA387-LBA387.	0.8	24
99	Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. <i>Annals of Oncology</i> , 2020, 31, 626-633.	0.6	23
100	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	6.1	22
101	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018, 14, 1629-1645.	1.1	22
102	Precision medicine in the adjuvant treatment of gastric cancer. <i>Lancet Oncology</i> , The, 2018, 19, 583-584.	5.1	22
103	Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	21
104	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
105	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	3.2	21
106	Pathological Evaluation of Mesocolic Resection Quality and Ex Vivo Methylene Blue Injection. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 197-204.	0.7	20
107	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 69-77.	1.1	20
108	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , 2017, 22, 1024-e89.	1.9	20

#	ARTICLE	IF	CITATIONS
109	Stents metálicos autoexpandibles como puente a la cirugía en el tratamiento del cáncer de colon izquierdo en oclusión. Análisis coste-beneficio y resultados oncológicos. Cirugía Española, 2017, 95, 143-151.	0.1	20
110	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. Annals of Oncology, 2019, 30, 1254-1264.	0.6	20
111	Role of epigenetic factors in the selection of the alternative splicing isoforms of human <i>KRAS</i> in colorectal cancer cell lines. Oncotarget, 2018, 9, 20578-20589.	0.8	20
112	Programmed colorectal cancer screening decreases incidence and mortality. Translational Gastroenterology and Hepatology, 2019, 4, 84-84.	1.5	19
113	Liquid biopsy: another tool towards tailored therapy in colorectal cancer. Annals of Oncology, 2018, 29, 7-8.	0.6	18
114	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.. Journal of Clinical Oncology, 2021, 39, 11-11.	0.8	18
115	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Annals of Oncology, 2012, 23, 2725-2730.	0.6	16
116	Personalised Treatment in Gastric Cancer: Myth or Reality?. Current Oncology Reports, 2016, 18, 41.	1.8	16
117	5-Fluorouracil, folinic acid, epirubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy. Annals of Oncology, 1993, 4, 753-757.	0.6	15
118	Treatment sequence of synchronously (liver) metastasized colon cancer. Digestive and Liver Disease, 2016, 48, 1119-1123.	0.4	15
119	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	1.3	15
120	Aurora kinases in ovarian cancer. ESMO Open, 2020, 5, e000718.	2.0	15
121	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. British Journal of Cancer, 2021, 125, 1261-1269.	2.9	14
122	Exploring better strategies for EGFR antibodies in colon cancer. Lancet Oncology, The, 2014, 15, 549-550.	5.1	13
123	In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells. Oncology Reports, 2016, 36, 3627-3634.	1.2	13
124	MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. Cancer Treatment Reviews, 2016, 49, 57-64.	3.4	13
125	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
126	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Investigational New Drugs, 2020, 38, 1774-1783.	1.2	13

#	ARTICLE	IF	CITATIONS
127	EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. <i>Scientific Reports</i> , 2020, 10, 3723.	1.6	13
128	Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3539-3539.	0.8	13
129	Implicaciones pronósticas del estudio estandarizado de los márgenes de resección en el cáncer de páncreas. <i>Cirugía Española</i> , 2014, 92, 532-538.	0.1	12
130	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.3	12
131	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	1.0	12
132	Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. <i>European Journal of Surgical Oncology</i> , 2021, 47, 276-284.	0.5	12
133	Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. <i>Supportive Care in Cancer</i> , 2022, 30, 1483-1491.	1.0	12
134	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016, 7, 63424-63436.	0.8	12
135	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , 2008, 19, vii266-vii272.	0.6	11
136	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
137	ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 9339.	1.6	11
138	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 669-669.	0.8	11
139	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	0.8	11
140	A multimodality approach to localized rectal cancer. <i>Annals of Oncology</i> , 2006, 17, x129-x134.	0.6	10
141	Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed. <i>Annals of Oncology</i> , 2018, 29, 2027-2028.	0.6	10
142	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.	1.0	10
143	Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. <i>ESMO Open</i> , 2021, 6, 100237.	2.0	10
144	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4009-4009.	0.8	10

#	ARTICLE	IF	CITATIONS
145	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0130543.	1.1	9
146	Combination of KIR2DS4 and Fc γ R1a polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2589.	1.6	9
147	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102798.	2.0	9
148	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 112, 12-19.	1.3	8
149	Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. <i>ESMO Open</i> , 2020, 5, e001107.	2.0	8
150	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 449-456.	1.5	7
151	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3575-3575.	0.8	7
152	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
153	Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 1053.	1.0	6
154	Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all. <i>Annals of Oncology</i> , 2015, 26, 617-619.	0.6	6
155	Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. <i>Histopathology</i> , 2019, 75, 517-525.	1.6	6
156	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	2.0	6
157	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000519.	2.0	5
158	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2020, 36, 1124-1128.	0.6	5
159	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. <i>Journal of Cancer Education</i> , 2021, 36, 556-560.	0.6	5
160	Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors. <i>Cancer Research</i> , 2021, 81, CT217-CT217.	0.4	5
161	mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. <i>Oncotarget</i> , 2017, 8, 104796-104805.	0.8	5
162	The Medical Oncology resident mentor: situation and workload. <i>Clinical and Translational Oncology</i> , 2019, 21, 304-313.	1.2	4

#	ARTICLE	IF	CITATIONS
163	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of tasisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	1.1	4
164	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , 2020, 5, e000929.	2.0	4
165	Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1433.	1.7	4
166	Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. <i>ESMO Open</i> , 2021, 6, 100148.	2.0	4
167	New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. <i>Oncotarget</i> , 2018, 9, 9100-9113.	0.8	4
168	Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients. <i>Cancers</i> , 2022, 14, 1146.	1.7	4
169	Heterogeneity of driver genes and therapeutic implications in colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1523-1525.	0.6	3
170	Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 351-352.	0.6	3
171	In the literature: June 2019. <i>ESMO Open</i> , 2019, 4, e000547.	2.0	3
172	New guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. <i>Annals of Oncology</i> , 2020, 31, 1287-1288.	0.6	3
173	Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). <i>Cancer Research</i> , 2021, 81, PD1-02-PD1-02.	0.4	3
174	Abstract P6-12-02: Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC). , 2015, , .		3
175	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 489-489.	0.8	3
176	Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1628-1639.	1.0	3
177	Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible. <i>ESMO Open</i> , 2022, 7, 100547.	2.0	3
178	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019, 8, 3120-3130.	1.3	2
179	Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1097-1098.	0.6	2
180	Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. <i>ESMO Open</i> , 2020, 5, e000800.	2.0	2

#	ARTICLE	IF	CITATIONS
181	Abstract PS11-11: Targeted safety events from a phase I/IIb study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)., 2021, , .		2
182	The COVID-19 pandemic could be a setback for gender equality in oncology and a key moment to push ahead with transformative policies. ESMO Open, 2021, 6, 100169.	2.0	2
183	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	0.8	2
184	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	0.8	2
185	Mechanisms of skin toxicity of paclitaxel: An in vitro preclinical assessment.. Journal of Clinical Oncology, 2020, 38, e15511-e15511.	0.8	2
186	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. Targeted Oncology, 2006, 1, 23-33.	1.7	1
187	Extending neoadjuvant chemotherapy in rectal cancer. Lancet Oncology, The, 2015, 16, 880-881.	5.1	1
188	Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. Annals of Oncology, 2017, 28, iii167.	0.6	1
189	Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points. Annals of Oncology, 2018, 29, 1493-1494.	0.6	1
190	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 2019, 4, e000533.	2.0	1
191	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2015, 33, 581-581.	0.8	1
192	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Gastroenterology & Hepatology, 2020, 43, 63-72.	0.2	1
193	In the literature: October 2021. ESMO Open, 2021, 6, 100285.	2.0	1
194	Growth factor receptor-related therapy for gastric cancer. European Journal of Cancer, 2011, 47, S324-S325.	1.3	0
195	In the literature: October 2016. ESMO Open, 2016, 1, e000103.	2.0	0
196	El tratamiento no quirúrgico del cáncer de recto localizado es una opción experimental. Cirugía Española, 2016, 94, 311-312.	0.1	0
197	Reply to the letter to the editor "How much evidence isn't in evidence-based guidelines?" by Johnson et al.. Annals of Oncology, 2016, 27, 550-551.	0.6	0
198	In the literature: February 2017. ESMO Open, 2017, 2, e000171.	2.0	0

#	ARTICLE	IF	CITATIONS
199	In the literature: April 2017. ESMO Open, 2017, 2, e000193.	2.0	0
200	In the literature: February 2018. ESMO Open, 2018, 3, e000322.	2.0	0
201	In the literature: December 2018. ESMO Open, 2018, 3, e000468.	2.0	0
202	Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer. Hepatobiliary Surgery and Nutrition, 2018, 7, 395-398.	0.7	0
203	In the literature: June 2018. ESMO Open, 2018, 3, e000401.	2.0	0
204	In the literature: August 2018. ESMO Open, 2018, 3, e000427.	2.0	0
205	In the literature: April 2018. ESMO Open, 2018, 3, e000362.	2.0	0
206	Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?. ESMO Open, 2018, 3, e000392.	2.0	0
207	Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Annals of Oncology, 2019, 30, 1409-1410.	0.6	0
208	In the literature: February 2019. ESMO Open, 2019, 4, e000490.	2.0	0
209	In the literature: October 2019. ESMO Open, 2019, 4, e000613.	2.0	0
210	In the literature: August 2018. ESMO Open, 2019, 4, e000563.	2.0	0
211	In the literature: April 2019. ESMO Open, 2019, 4, e000513.	2.0	0
212	In the literature: February 2020. ESMO Open, 2020, 5, e000680.	2.0	0
213	In the literature: June 2020. ESMO Open, 2020, 5, e000832.	2.0	0
214	In the literature: August 2020. ESMO Open, 2020, 5, e000909.	2.0	0
215	In the literature: December 2019. ESMO Open, 2020, 5, e000642.	2.0	0
216	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Gastroenterology (English Edition), 2020, 43, 63-72.	0.0	0

#	ARTICLE	IF	CITATIONS
217	In the literature: April 2020. ESMO Open, 2020, 5, e000749.	2.0	0
218	In the literature: December 2020. ESMO Open, 2021, 6, 100009.	2.0	0
219	In the literature: February 2021. ESMO Open, 2021, 6, 100061.	2.0	0
220	In the literature: April 2021. ESMO Open, 2021, 6, 100116.	2.0	0
221	In the literature: June 2021. ESMO Open, 2021, 6, 100186.	2.0	0
222	Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Annals of Oncology, 2021, 32, 1190-1191.	0.6	0
223	In the literature: August 2021. ESMO Open, 2021, 6, 100247.	2.0	0
224	Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. European Journal of Surgical Oncology, 2021, 47, 2697.	0.5	0
225	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 447-447.	0.8	0
226	Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.. Journal of Clinical Oncology, 2014, 32, 3551-3551.	0.8	0
227	In the literature: October 2018. ESMO Open, 2018, 3, e000447.	2.0	0
228	A preclinical model for skin sensitization prediction of antineoplastic drugs.. Journal of Clinical Oncology, 2020, 38, e15643-e15643.	0.8	0
229	In the literature: October 2020. ESMO Open, 2020, 5, e001048.	2.0	0
230	In the literature: December 2021. ESMO Open, 2022, 7, 100352.	2.0	0
231	Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Seminars in Oncology, 1997, 24, S15-40-S15-43.	0.8	0
232	In the literature: February 2022. ESMO Open, 2022, 7, 100411.	2.0	0
233	A phase I study of radiation therapy (RT) with concurrent oxaliplatin (OXL), cisplatin (P) and protected infusion 5-fluorouracil (FU) for locally advanced esophageal (ES) or gastroesophageal (GE) carcinoma. Journal of Clinical Oncology, 2004, 22, 4243-4243.	0.8	0
234	In the literature: April 2022. ESMO Open, 2022, 7, 100479.	2.0	0